Linezolid Surveillance Results for the United States: LEADER Surveillance Program 2011

被引：39

作者：

Flamm, Robert K. ^{[1
]}

Mendes, Rodrigo E. ^{[1
]}

Ross, James E. ^{[1
]}

Sader, Helio S. ^{[1
]}

Jones, Ronald N. ^{[1
,2
]}

机构：

[1] JMI Labs, N Liberty, IA USA

[2] Tufts Univ, Sch Med, Boston, MA 02111 USA

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2013年 / 57卷 / 02期

关键词：

SPECTRUM ANALYSIS; MEDICAL-CENTERS; NOSOCOMIAL PNEUMONIA; VANCOMYCIN; INFECTIONS;

D O I：

10.1128/AAC.02112-12

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

The LEADER surveillance program monitors the in vitro activity of linezolid and comparator agents against Gram-positive bacteria in the United States. In its eighth consecutive year ( 2011), a total of 60 medical centers from the United States, including seven medical centers specializing in children's health care contributed a total of 7,303 Gram-positive pathogens. The MIC90 value for Staphylococcus aureus was 2 mu g/ml, and for coagulase-negative staphylococci, enterococci, Streptococcus pneumoniae, beta-hemolytic streptococci, and viridans group streptococci, the MIC90 was 1 mu g/ml. The "all organism" linezolid-resistant and nonsusceptible rate was only 0.19%.

引用

页码：1077 / 1081

页数：5

共 19 条

[1]

Clinical and Laboratory Standards Institute, 2012, M02A11 CLIN LAB STA

[2]

Clinical and Laboratory Standards Institute, 2012, M100S22 CLIN LAB STA

[3]

Clinical and Laboratory Standards Institute, 2012, M07A9 CLIN LAB STAND

[4] In vitro activity of linezolid against key gram-positive organisms isolated in the United States: Results of the LEADER 2004 surveillance program [J].